Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy A Phase Ib/II Clinical Study
Latest Information Update: 17 Feb 2026
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan (Primary)
- Indications Malignant ascites
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 17 Feb 2026 New trial record